Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
AIDS ; 34(10): 1497-1507, 2020 08 01.
Article in English | MEDLINE | ID: mdl-32675563

ABSTRACT

BACKGROUND: Previous studies have suggested that hepatocellular carcinoma (HCC) has an aggressive presentation and a shorter survival in people with HIV (PWH). This could be due to later diagnosis or lower rates of HCC treatment, and not to HIV infection itself. AIM: :: To assess the impact of HIV on HCC survival in hepatitis C virus (HCV)-infected patients. METHODS: Multicenter cohort study (1999-2018) of 342 and 135 HCC cases diagnosed in HIV/HCV-infected and HCV-monoinfected patients. Survival after HCC diagnosis and its predictors were assessed. RESULTS: HCC was at Barcelona-Clinic Liver-Cancer (BCLC) stage 0/A in 114 (33%) HIV/HCV-coinfected and in 76 (56%) HCV-monoinfected individuals (P < 0.001). Of them, 97 (85%) and 50 (68%) underwent curative therapies (P = 0.001). After a median (Q1-Q3) follow-up of 11 (3-31) months, 334 (70%) patients died. Overall 1 and 3-year survival was 50 and 31% in PWH and 69 and 34% in those without HIV (P = 0.16). Among those diagnosed at BCLC stage 0/A, 1 and 3-year survival was 94 and 66% in PWH whereas it was 90 and 54% in HIV-negative patients (P = 0.006). Independent predictors of mortality were age, BCLC stage and α-fetoprotein levels. HIV infection was not independently associated with mortality [adjusted hazard ratio (AHR) 1.57; 95% confidence interval: 0.88-2.78; P = 0.12]. CONCLUSION: HIV coinfection has no impact on the survival after the diagnosis of HCC in HCV-infected patients. Although overall mortality is higher in HIV/HCV-coinfected patients, this seem to be related with lower rates of early diagnosis HCC in HIV-infected patients and not with HIV infection itself or a lower access to HCC therapy.


Subject(s)
Carcinoma, Hepatocellular/mortality , Coinfection , HIV Infections , Hepatitis C, Chronic , Liver Neoplasms/mortality , Cohort Studies , HIV Infections/complications , Hepacivirus , Hepatitis C, Chronic/complications , Humans , Liver Neoplasms/virology , Survival Rate
2.
AIDS ; 33(2): 269-278, 2019 02 01.
Article in English | MEDLINE | ID: mdl-30325782

ABSTRACT

OBJECTIVE: To assess the performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma (HCC) in HIV-infected patients. METHODS: The GEHEP-002 cohort recruits HCC cases diagnosed in HIV-infected patients from 32 centers across Spain. The proportion of 'ultrasound lack of detection', defined as HCC diagnosed within the first 3 months after a normal surveillance ultrasound, and the proportion of 'surveillance failure', defined as cases in which surveillance failed to detect HCC at early stage, were assessed. To assess the impact of HIV, a control population of 104 HCC cases diagnosed in hepatitis C virus-monoinfected patients during the study period was used. RESULTS: A total of 186 (54%) out of 346 HCC cases in HIV-infected patients were diagnosed within an ultrasound surveillance program. Ultrasound lack of detection occurred in 16 (8.6%) of them. Ultrasound surveillance failure occurred in 107 (57%) out of 186 cases diagnosed by screening, whereas this occurred in 18 (29%) out of 62 diagnosed in the control group (P < 0.0001). HCC cases after ultrasound surveillance failure showed a lower frequency of undetectable HIV viral load at diagnosis. The probability of 1-year and 2-year survival after HCC diagnosis among those diagnosed by screening was 56 and 45% in HIV-infected patients, whereas it was 79 and 64% in HIV-negative patients (P = 0.038). CONCLUSION: The performance of ultrasound surveillance of HCC in HIV-infected patients is very poor and worse than that shown outside HIV infection. A HCC surveillance policy based on ultrasound examinations every 6 months might be insufficient in HIV-infected patients with cirrhosis.


Subject(s)
Carcinoma, Hepatocellular/diagnostic imaging , HIV Infections/complications , Liver Neoplasms/diagnostic imaging , Ultrasonography/methods , Aged , Carcinoma, Hepatocellular/epidemiology , Epidemiological Monitoring , Female , Humans , Liver Neoplasms/epidemiology , Male , Middle Aged , Retrospective Studies , Sensitivity and Specificity , Spain/epidemiology
3.
J Antimicrob Chemother ; 73(9): 2435-2443, 2018 09 01.
Article in English | MEDLINE | ID: mdl-29982683

ABSTRACT

Objectives: To assess the impact of all-oral direct-acting antiviral agent (DAA) regimens on the risk of hepatocellular carcinoma (HCC) in HIV/HCV-coinfected patients with cirrhosis. Methods: This was a multicentre prospective cohort study recruiting HIV/HCV-coinfected patients with a new diagnosis of compensated cirrhosis. Patients were followed up until HCC, death or the censoring date (March 2017). The primary endpoint was the emergence of HCC. The incidence rate (IR) (95% CI) of HCC in different groups was computed. Time-to-event analyses were performed to identify predictors of HCC emergence. Results: The study included 495 HIV/HCV-coinfected patients with cirrhosis. After a median (IQR) follow-up of 59 (27-84) months, 22 (4.4%; 95% CI 2.6-6.3) patients developed an HCC. The IR (95% CI) of HCC was 0.93 (0.06-1.42) per 100 person-years (PY). Three hundred and three (61%) patients achieved sustained virological response (SVR) during follow-up, 79 after interferon (IFN)-based regimens and 224 after an all-oral DAA regimen. The IR (95% CI) of HCC after all-oral DAA was 0.35 (0.14-0.85) per 100 PY whereas it was 1.79 (1.11-2.88) per 100 PY in the remaining cohort (P = 0.0005). When only patients with SVR were considered, the IR (95% CI) of HCC after all-oral DAA was 0.32 (0.12-0.86) whereas it was 0 per 100 PY among those with SVR after IFN-based therapies (P = 0.27). Achieving SVR with an all-oral DAA regimen during follow-up was independently associated with a lower risk of HCC emergence (subhazard ratio 0.264; 95% CI 0.070-0.991; P = 0.049). Conclusions: SVR with all-oral DAA regimens reduces the risk of HCC in HIV/HCV-coinfected patients with compensated cirrhosis.


Subject(s)
Antiviral Agents/therapeutic use , Carcinoma, Hepatocellular/prevention & control , HIV Infections/complications , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/drug therapy , Liver Cirrhosis/complications , Liver Cirrhosis/drug therapy , Adult , Coinfection/complications , Coinfection/drug therapy , Female , Follow-Up Studies , Humans , Incidence , Male , Middle Aged , Prospective Studies , Risk Assessment , Sustained Virologic Response
4.
Vet Clin Pathol ; 47(1): 29-37, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29364544

ABSTRACT

BACKGROUND: Hematologic and serum biochemical reference values obtained from captive or free-ranging wildlife populations may not be comparable as there can be significant variations due to preanalytic and analytic differences, including methods of capture and restraint, overall management in captivity including diet and composition of animal groups, and analytic methods being used. Hematology and serum biochemistry have never been studied in captive or free-ranging populations of Sechuran foxes (Lycalopex sechurae). OBJECTIVES: The purposes of the study were to determine hematologic and serum biochemical RI in Sechuran foxes and to explore differences in these variables related to sex and overall life circumstances. METHODS: Blood samples were obtained from 15 free-ranging and 15 captive Sechuran foxes. Hematology variables were assessed by blood smear examination and automated analyzer methodology. Serum biochemical analysis was performed by automated analyzer methodology. Descriptive statistics were calculated for each variable. Data obtained from free-ranging and captive groups were statistically compared and RIs were calculated. RESULTS: Captive Sechuran foxes had significantly (P < .05) higher MCH, MCHC, and eosinophil counts and significantly lower band neutrophil counts than free-ranging foxes. Free-ranging Sechuran foxes had significantly (P < .05) higher serum lipase and globulins and significantly lower albumin, total bilirubin, and indirect bilirubin than captive foxes. CONCLUSIONS: These findings suggest that there are hematologic and serum biochemical differences between captive and free-ranging Sechuran fox populations. Hence, such differences should be considered when using these variables to assess the health status of this species.


Subject(s)
Foxes/blood , Animals , Animals, Wild/blood , Animals, Zoo/blood , Blood Chemical Analysis/veterinary , Female , Hematology , Male , Peru , Reference Values
SELECTION OF CITATIONS
SEARCH DETAIL
...